PRINCETON, N.J. --(BUSINESS WIRE)--Jun. 9, 2023-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 6 new
PRINCETON, N.J. --(BUSINESS WIRE)--Jun. 2, 2023-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at the following investor conferences in June:
Reported JELMYTO ® Q1 2023 net product revenues of $17.2 million , an increase of ~27% from Q1 2022 Complete Response data from ENVISION pivotal trial and topline data readout from ATLAS trial on track for summer 2023 PRINCETON, N.J. --(BUSINESS WIRE)--May 11, 2023-- UroGen Pharma Ltd.
Conference Call and Webcast Scheduled for Thursday, May 11, 2023 , at 10:00 AM ET PRINCETON, N.J. --(BUSINESS WIRE)--May 4, 2023-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today
New Retrospective Study Presented at AUA 2023 Reports Use of JELMYTO in Treating Patients with Upper Tract Urothelial Cancer After Complete Endoscopic Ablation PRINCETON, N.J. --(BUSINESS WIRE)--May 1, 2023-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and
PRINCTON, N.J.--(BUSINESS WIRE)--Apr. 30, 2023-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis from the first and largest
- Fireside Chat May 2, 2023 from 10:00 – 10:30 AM ET - PRINCETON, N.J. --(BUSINESS WIRE)--Apr. 25, 2023-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will
Reported JELMYTO® full year 2022 net product revenues of $64.4 million , an increase of 34% from full year 2021 Completed enrollment of the ENVISION Phase 3 pivotal clinical trial for UGN-102 for LG-IR-NMIBC Topline data readout from ATLAS clinical study and Complete Response from ENVISION pivotal
Conference Call and Webcast Scheduled for Thursday, March 16, 2023 , at 10:00 AM ET PRINCETON, N.J. --(BUSINESS WIRE)--Mar. 9, 2023-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers,
PRINCETON, N.J. --(BUSINESS WIRE)--Mar. 6, 2023-- UroGen Pharma Ltd. (Nasdaq: URGN) a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 7 new
